STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
- Country
- Netherlands
- Type
- Beneficiary
- Website
- www.nki.nl
- Grants received
- 138
Funding record
- 138 grants on record
- €110,618,593.83 awarded in total
- 2008–2026 span of the record
Grants recorded here are the ones our sources publish, and the total is the sum of those. It is not a statement of this organisation's total funding.
Programmes
- Seventh Framework Programme
- Horizon Europe Framework Programme
- European Research Council
- Horizon 2020 Framework Programme
56 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations this one has been funded alongside on two or more projects. A single shared consortium is not counted: the largest here has 195 members, and being on one list together is not a collaboration.
- KAROLINSKA INSTITUTET
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
- EUROPEAN MOLECULAR BIOLOGY LABORATORY
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
- ACADEMISCH ZIEKENHUIS LEIDEN
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Calls from this organisation
No published calls from this organisation.
Grants received
- Evolution of T cell reactivity against somatic mutations across human colon cancer stages with single-cell genomics and synthetic T cell specificity screening
- PUBLIC ENGAGEMENT IN RESEARCH INFRASTRUCTURES FOR MISSION CANCER: MANAGING COMPLEXITY OF EMERGING TECHNOLOGIES
- Prediction and prevention of late effects in AYA cancer survivors – An effort to understand, predict and prevent late effects in AYAs 15-39 years of age, with a focus on fertility and gonadal toxicity
- Single-molecule visualization of transcription dynamics to understand regulatory mechanisms of cofactors
- Deconstructing adaptive evolution of metastasis
- Using senolytic agents to suppress the toxicity of chemotherapy
- Why do transcription factors bind what they bind when they bind?
- Causes and consequences of aberrant mRNA translation in cancer
- Deep genetics to study and uncover ‘hidden’ biology
- Paradoxical activation of oncogenic signaling as a cancer treatment strategy.
- Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research
- Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers
- Catalysis for Cancer Treatment.
- PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials
- A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.